Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1096 participants.

Also called NCT07241520

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,096 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07241520
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07241520. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-08 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
Acronym
SAIL
Condition
Acute Ischemic Stroke
Intervention (Drug)
SHPL-49 Injection
Intervention (Drug)
Placebo Injection
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited (class: industry)
Collaborator
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct07241520
Content hash
846b60f8bb74103db9610593efa2a6e9e95328bd3627e7fd09fe1870462d5939